Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-13
2008-05-13
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S008100
Reexamination Certificate
active
07371725
ABSTRACT:
The present invention is concerned with a method and composition for use in the medical art. It relates to the prevention and/or minimization of Spondyloarthropathies (SpA) and/or SpA enthesitis. SpA are an important group of chronic inflammatory disorders, affecting both the axial and peripheral skeleton. A particular method and composition optionally including a suitable dispensing device for such compositions can be used for ameliorating or preventing SpA. The invention applies to human and veterinary applications. To date, no single therapeutic approach has proven universally effective in preventing SpA or ameliorating SpA. Therefore, there is a need for compositions and methods which may be used safely and effectively to prevent SpA in a variety of different contexts.
REFERENCES:
patent: 5843775 (1998-12-01), Valenzuela et al.
patent: 5932216 (1999-08-01), Celeste et al.
patent: 6537966 (2003-03-01), Duan et al.
patent: WO 96/01845 (1996-01-01), None
patent: WO 98/49296 (1998-11-01), None
patent: WO 99/61044 (1999-12-01), None
patent: WO 00/56879 (2000-09-01), None
patent: WO 02/080952 (2002-10-01), None
patent: WO 02/080952 (2002-10-01), None
patent: WO 02/100426 (2002-12-01), None
Massague, 1998, Ann. Rev. Biochem. 67:753-791.
Natsume et al., “Interaction Between Soluble Type I Receptor for Bone Morphogenetic Protein and Bone Morphogenetic Protein-4,”The Journal of Biological Chemistry, 272:11535-11540 (1997).
EPO Communication issued in EP Application 03 702 222.5—1216 (dated Aug. 2, 2007).
McGonagle et al., “Enthesitis in spondyloarthropathy,”Current Opinion in Rheumatology11:244-250 (1999).
Natsume et al., “Interaction Between Soluble Type I Receptor for Bone Morphogenetic Protein and Bone Morphogenetic Protein-4”,The Journal of Biological Chemistry, 272:11535-11540 (1997).
Lories Rik
Luyten Frank
Clark & Elbing LLP
K.U. Leuven Research & Development
Kemmerer Elizabeth C.
LandOfFree
Spondyloarthropathies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Spondyloarthropathies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Spondyloarthropathies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2791227